Bleichroeder LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Bleichroeder LP
CRD #304295
SEC #801-117171
CIK #0001781002
AUM 2,431.2 M (2026-03-16)
Employees 7 (86% Investors, 0% Brokers)
Fees
Minimum
Phone212-984-3815
Address1345 Avenue of The Americas
New York, NY 10105
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/16/2026) [Brochure]
Item 5: Fees and Compensation
Bleichroeder typically receives compensation from its Clients from the following sources: (a) fees
based on a percentage of assets under management; and (b) fees or allocations based on a
percentage of the performance of the Client accounts. Fees for Managed Account clients are
negotiable. Bleichroeder is entitled to enter into side letter agreements with some Investors in the
Funds varying the terms of their investment, including lower fee arrangements. Current and
prospective clients should carefully review all fees charged by Bleichroeder. Different fees are
charged to different Clients and Investors, and fees can be waived, rebated, or reduced for certain
Clients and Investors.

Management Fee:

In consideration for its services to the Funds, Bleichroeder is generally entitled to a management
fee measured as a percentage of average monthly value of each Investor’s capital account balance
during the particular quarter (the “Management Fee”). Bleichroeder, at its sole discretion can offer
to investors different classes of interest in the Funds with preferential terms. For more details
regarding the Management Fee and different classes of interests in the Funds, please refer to the
applicable Fund Governing Documents.

Generally, the Management Fee is calculated and paid each calendar quarter in arrears.
Bleichroeder or the General Partner, as applicable, can reduce or eliminate the Management Fee
with respect to any Investor in its sole discretion. Bleichroeder and its affiliates may not be charged
any Management Fees with respect to their interests in the Funds.

Performance based Compensation:

Subject to certain terms and limitations disclosed in the Governing Documents, Bleichroeder is
entitled to receive performance-based compensation (the “Incentive Allocation”) with respect to
the Funds in an amount equal to a percentage of the net capital appreciation attributable to each
Investor’s capital account in the Fund (after taking into account expenses of the Fund, including

any Management Fees). The Incentive Allocation is generally payable annually after year‐end or
at the time the Investor withdraws from the Fund if before year‐end. The Incentive Allocation will
be calculated on the basis of the aggregate balance in an Investor’s capital account, irrespective of
how many or when capital contributions are made to such capital account by such Investor.

An Incentive Allocation can also be subject to what is commonly known as a “high water mark.”
That is, if a capital account underperforms during a calendar year, the net underperformance will
be recorded and carried forward to future calendar years (such amount is referred to as the “Loss
Carryforward”), and Bleichroeder will not receive the Incentive Allocation with respect to such
capital account for future calendar years until the Loss Carryforward amount has been recovered
(i.e., when the Loss Carryforward amount has been exceeded by the cumulative net
outperformance in the calendar years following the Loss Carryforward), unless otherwise noted.
Once the Loss Carryforward has been recovered, the Incentive Allocation shall generally be based
on the excess net capital appreciation over the Loss Carryforward amount, rather than on all net
capital appreciation. The “high water mark” procedure prevents Bleichroeder from receiving the
Incentive Allocation for net capital appreciation that simply restores previous underperformance
and is intended to ensure that the Incentive Allocation is based on the long-term performance of
the Fund.

In some instances, Clients may pay Bleichroeder a performance-based compensation in the form
of a carried interest (“Carried Interest”). The Carried Interest is typically calculated based on a
share of capital gains on or capital appreciation of the assets of each Fund, as negotiated and
determined at the time such Fund is established and as set forth in its Governing Documents. The
Carried Interest is generally not paid until all investors have received aggregate distributions equal
to the sum of their capital contributions to the Fund and subject to a specified, annually
compounded preferred return, if any and a related general partner catch-up provision.

Managed Account Clients can also be subject to the Management Fee and performance-based
compensation similar to those described above. The level of compensation can vary by Client,
based on a Client’s investment objectives and limitations. Bleichroeder is generally entitled to
deduct fees directly from the Client accounts.

Except as provided herein or the constituent Governing Documents, Bleichroeder renders its
services to the Clients at its own expense and is responsible for its overhead expenses including:
office rent; utilities; furniture and fixtures; stationery; secretarial/internal administrative services;
salaries and bonuses; entertainment expenses; employee insurance and payroll taxes.

Other Expenses Charged to the Clients:

Expenses described below are general in nature and not intended to be exhaustive. For more
information regarding expenses associated with investing in a particular Fund investment or
strategy, please refer to applicable Fund Governing Documents. Managed Account expenses vary

by Client and are negotiated directly with each prospective client prior to commencement of
advisory services and over time.

As detailed in applicable Fund documentation, investors are generally subject to the following
expenses associated with their investments in a Fund, in addition to the Management Fee and
Incentive Allocation described above: the organizational and initial offering costs of the Fund,
including legal, accounting, printing, marketing and comparable expenses.

Each Investor bears a Fund’s pro rata share of operating expenses that include, but are not limited
to: legal, compliance, auditing, accounting and other professional expenses, administration
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/16/2026) [Brochure]
Item 7: Types of Clients
As mentioned in Item 4, Bleichroeder provides investment advisory services to Managed Accounts
and Funds. Interests in the Funds is offered only to sophisticated and qualified investors, including
but not limited to: high-net-worth individuals, family offices and institutions.

The minimum investment in the Funds is generally $100,000, although Bleichroeder can elect to
accept a lesser amount in its sole discretion.

As of the date of this Brochure, Bleichroeder does not have a set minimum to open a Managed
Account.
Sector Form 13F Holdings Value ($M)
SPDR Gold Trust 204.4
Roman DBDR Tech Acquisition Corp 67.9
Resolute Holdings Management Inc 51.0
Linde PLC 33.9
Mdxhealth Sa 17.0
Intellicheck Mobilisa Inc 14.5
Information Systems Associates Inc 11.2
Identive Group Inc 10.7
Blackstone Group LP 10.4
Precision Biosciences Inc 9.1
View All
Holdings by Sector ($M)
120096072048024002019202120242027
Type Form D Funds Date Sold AUM
PE Bleichroeder Private Investments LLC Series 2 2025-03-28 11.9 M
HF Coherence Equity Partners LP 2022-04-28 26.8 M
PE Bleichroeder Private Investments LLC 2021-03-23
Other Bleichroeder UV LLC 2021-03-23 356.3 M
HF 21 April Fund Ltd [2014-03-31] 179.6 M 441.0 M
Filed 2012-03-12 (D/A) · Exemption 506, 3(c), 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF 21 April Fund LP [2012-03-30] 161.3 M 194.4 M
Filed 2023-03-30 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Biotechnology Master Fund Ltd [2012-03-30] 68.2 M 4.1 M
Filed 2018-03-13 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 33 0.4
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 5 1.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 6 0.9
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 13 0.1
(n) Other 0 0.0
Total 57 2.4
By Discretionary
Discretionary 57 2.4
Non-Discretionary 0 0.0
Total 57 2.4
By Non-United States Persons
Non-United States Persons 0.5
United States Persons 1.9
Total 57 2.4
Form D Directors Role # Filings # Firms 2011 - 2026
Martin Byrne Director 130 21
Steven Schaefer Director 21 5
First Eagle Investment Management LLC Executive Officer 20 4
Tim Tabor Executive Officer 15 4
Curtis Lowell Jr Director 10 4
EDGAR Form CIK 2011 - 2026
13F-HR [0001781002]
3 [0001781002]
4 [0001781002]
SC 13D [0001781002]
SC 13G [0001781002]
Form 13D/13G Filer Form 13D/13G Subject Filed
Bleichroeder LP Envoy Medical Inc [2026-05-14]
Bleichroeder LP Ernexa Therapeutics Inc [2026-05-14]
Bleichroeder LP Cellectar Biosciences Inc [2025-11-14]
Bleichroeder LP Fluent Inc [2025-11-14]
Bleichroeder LP Neuroone Medical Technologies Corp [2025-08-14]
Bleichroeder LP Precision Biosciences Inc [2025-08-14]
Bleichroeder LP First Eagle Real Estate Debt Fund [2025-04-07]
Bleichroeder LP Curis Inc [2025-03-31]
Bleichroeder LP Smartkem Inc [2025-03-31]
Bleichroeder LP Aptose Biosciences Inc [2025-02-13]
View All
Firm Profile (Form ADV)
Clients10 (18 non-US)
ServesInstitutional, Retail
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
Bleichroeder LP
Liqtech International Inc
First Eagle Real Estate Debt Fund
Scientific Industries Inc
DUOS Technologies Group Inc
GPGI Inc
Identive Group Inc
Intevac Inc
Durect Corp
First Eagle Credit Opportunities Fund
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
First Eagle Real Estate Debt Fund FERLX
Shares of Beneficial Interest, Class I Shares
2025-08-06 Buy 633,161.85 $25.27 16,000,000
First Eagle Real Estate Debt Fund FERLX
Shares of Beneficial Interest, Class I Shares
2025-04-30 Buy 354,645.18 $25.16 8,922,873
Scientific Industries Inc SCND
Common Stock
2025-04-18 Buy 250,000 $1.00 250,000
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
2025-04-18 Buy 250,000
Liqtech International Inc LIQT
Warrants to Purchase Common Stock · derivative
2025-03-26 Other 531,250
Liqtech International Inc LIQT
Warrants to Purchase Common Stock · derivative
2025-03-26 Other 531,250
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Option exercise 300,000 $0.00
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Option exercise 44,644 $0.00
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
2024-09-19 Other 12,500 $1,000.00 12,500,000
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
2024-09-19 Other 12,500 $1,000.00 12,500,000
DUOS Technologies Group Inc DUOT
Common Stock
2024-09-19 Option exercise 344,644 $2.61 899,521
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Other 300,000
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Other 44,644
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Other 300,000
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-09-19 Other 44,644
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
2024-07-22 Buy 300,000
GPGI Inc cmpo
Common Stock
2024-05-09 Buy 800,000 $6.50 5,200,000
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
2024-03-22 Buy 1,000 $1,000.00 1,000,000
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
2023-12-13 Other 278,947
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
2023-12-13 Buy 960,000
showing 20 of 124 most recent transactions
Related Firms State AUM
Bleichroeder LP
NY 2,431.2 M
Goldiron GP LLC
NY 60.2 M
Comparable Firms State AUM
Brevet Capital Management LLC
NY 2,566.0 M
Basso Capital Management LP
CT 2,558.1 M
Chickasaw Capital Management LLC
TN 2,545.9 M
North Star Investment Management Corporation
IL 2,502.4 M
Spruceview Capital Partners LLC
CO 2,342.5 M
Baldwin Wealth Partners LLC
MA 2,334.7 M
Cramer Rosenthal McGlynn LLC
CT 2,266.4 M
Clear Haven Capital Management LLC
NY 2,183.6 M
Kintegral Advisory LLC
NY 2,138.8 M
NFC Investments LLC
TN 2,137.5 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com